LXEO
$6.34-0.23 (-3.54%)
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in ph...
Recent News
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference
Lexeo Therapeutics (NASDAQ:LXEO) executives outlined the company’s focus on precision medicines for inherited cardiac diseases during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, highlighting progress across two lead gene therapy programs targeting Friedreich’s at
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit
Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its lead gene therapy programs during a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit. Company focus: genetic medicines for cardiac disease CEO Nolan Townsend
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list. TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm believes that […]
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential […]